[米托蒽醌治疗多发性硬化症患者时发生的急性心力衰竭]
[Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
作者信息
Feuillet L, Guedj E, Eusebio A, Malikova I, Pelletier J, Mundler O, Ali Chérif A
机构信息
Service de Neurologie, CHU La Timone, Marseille.
出版信息
Rev Neurol (Paris). 2003 Dec;159(12):1169-72.
Mitoxantrone is an immunosuppressive drug usually delivered in severe relapsing remitting multiple sclerosis. It can also be used in secondary progressive and progressive relapsing remitting multiple sclerosis. Left ventricular ejection fraction has to be monitored because of the cardiotoxicity risk of mitoxantrone. Acute cardiac side effects in multiple sclerosis have not yet been described. We report the single case of an acute heart failure occurring in a cohort of more than 800 patients treated with mitoxantrone. We discuss about interruption criteria as maximal cumulative dose allowed and left ventricular ejection fraction cut off value.
米托蒽醌是一种免疫抑制药物，通常用于治疗严重复发缓解型多发性硬化症。它也可用于继发进展型和进展复发缓解型多发性硬化症。由于米托蒽醌存在心脏毒性风险，必须监测左心室射血分数。多发性硬化症的急性心脏副作用尚未见报道。我们报告了在一组接受米托蒽醌治疗的800多名患者中发生的一例急性心力衰竭病例。我们讨论了中断标准，如允许的最大累积剂量和左心室射血分数临界值。
Zotero 插件